Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 54: 1528-1536, 2008. First published July 24, 2008; 10.1373/clinchem.2008.104653
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2008.104653v1
54/9/1528    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chan, K. C. A.
Right arrow Articles by Lo, Y. M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chan, K. C. A.
Right arrow Articles by Lo, Y. M. D.
(Clinical Chemistry. 2008;54:1528-1536.)
© 2008 American Association for Clinical Chemistry, Inc.

Molecular Diagnostics and Genetics

Quantitative Analysis of Circulating Methylated DNA as a Biomarker for Hepatocellular Carcinoma

K. C. Allen Chan1,2, Paul B. S. Lai3, Tony S. K. Mok1,4, Henry L. Y. Chan1,5, Chunming Ding6,7, S. W. Yeung2 and Y. M. Dennis Lo1,2,7,a

1 State Key Laboratory in Oncology in South China, Sir Y. K. Pao Centre for Cancer, Departments of 2 Chemical Pathology, 3 Surgery, 4 Clinical Oncology, and 5 Medicine and Therapeutics, 6 Stanley Ho Centre for the Emerging Infectious Diseases, and 7 Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong Special Administrative Region, China.

aAddress correspondence to this author at: Department of Chemical Pathology, Rm. 38023, 1/F, Clinical Science Building, Prince of Wales Hospital, 30-32 Ngan Shing St., Shatin, New Territories, Hong Kong SAR. Fax +852 2636 5090; e-mail loym{at}cuhk.edu.hk.

Background: Hypermethylation of the RASSF1A [Ras association (RalGDS/AF-6) domain family member 1A] gene is frequently observed in hepatocellular carcinoma (HCC). We evaluated the analysis of circulating hypermethylated RASSF1A for detecting HCC and assessing its prognosis.

Methods: In module 1, we studied 63 pairs of HCC patients and age- and sex-matched chronic hepatitis B virus (HBV) carriers, as well as 50 healthy volunteers. In module 2, we studied 22 HCC patients with cancer detected through a surveillance program. The concentrations of circulating hypermethylated RASSF1A sequences were measured by real-time PCR after digestion with a methylation-sensitive restriction enzyme.

Results: We detected hypermethylated RASSF1A sequences in the sera of 93% of HCC patients, 58% of HBV carriers, and 8% of the healthy volunteers. The median RASSF1A concentrations for the HCC patients and HBV carriers were 7.70 x 105 copies/L and 1.18 x 105 copies/L, respectively (P < 0.01). The detection of low concentrations in HBV carriers is consistent with previous findings that RASSF1A hypermethylation is an early event in HCC pathogenesis and can be found in premalignant liver tissues. Use of a marker cutoff value of 1 x 106 copies/L also identifies 50% of {alpha}-fetoprotein-negative HCC cases. Patients with higher RASSF1A concentrations at diagnosis or 1 year after tumor resection showed poorer disease-free survival (P < 0.01). For the HBV carriers who underwent HCC surveillance and subsequently developed HCC, the circulating concentration of RASSF1A increased significantly from the time of enrollment to cancer diagnosis (P = 0.014).

Conclusions: Detection and quantification of circulating methylated RASSF1A sequences are useful for HCC screening, detection, and prognostication.




The following articles in journals at HighWire Press have cited this article:


Home page
 Neuro OncologyHome page
I. Lavon, M. Refael, B. Zelikovitch, E. Shalom, and T. Siegal
Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades
Neuro Oncology, February 1, 2010; 12(2): 173 - 180.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
S. Huang, H. Li, X. Ding, and C. Xiong
Presence and Characterization of Cell-Free Seminal RNA in Healthy Individuals: Implications for Noninvasive Disease Diagnosis and Gene Expression Studies of the Male Reproductive System
Clin. Chem., November 1, 2009; 55(11): 1967 - 1976.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
T. deVos, R. Tetzner, F. Model, G. Weiss, M. Schuster, J. Distler, K. V. Steiger, R. Grutzmann, C. Pilarsky, J. K. Habermann, et al.
Circulating Methylated SEPT9 DNA in Plasma Is a Biomarker for Colorectal Cancer
Clin. Chem., July 1, 2009; 55(7): 1337 - 1346.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
E C W Hung, R W K Chiu, and Y M D Lo
Detection of circulating fetal nucleic acids: a review of methods and applications
J. Clin. Pathol., April 1, 2009; 62(4): 308 - 313.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Association for Clinical Chemistry.